Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Company Profile and bullboard matches:

MSSEL , MBDC , INDB
Sort by: Date|Relevance

Speculative stock picks for a scary market environment

We believe this is a meltdown, not a pullback and consolidation for another upward move. On Thursday, January 21, at 1:08 pm we issued the following market alert to our subscribers: “We believe this is the start of a large correction…..we sold all positions –DANGER.&CloseC...
J.W. Cotton | October 28, 2012 |

Relmada Therapeutics Stock Soars on Phase 2 Depression Study Results

Shares of Relmada Therapeutics have traded wildly today after it announced Phase 2 results for its anti-depressant drug dextromethadone. The firm's shares have traded 100–200% higher today and the stock was halted several times trading due to extreme price volatility. ...
Streetwise Reports | October 16, 2019 |

T2 Biosystems Receives BARDA Contract to Fight Antimicrobial Resistance, Shares Up More than 88%

This healthcare diagnostics stock rose more than 88% on Wednesday following the award of a BARDA contract that could be worth up to $69 million. On Wednesday morning, T2 BioSystems Inc. (TTOO:NASDAQ) announced receipt of funding from the U.S. Department of Health a...
Streetwise Reports | September 12, 2019 |

Buzz on the Bullboards: Summer market madness

It is the first full day of summer and traders south of the border returned to the markets after a long weekend selling off shares on their first day back. Baytex Energy Stock made news after closing its acquisition of Ranger Oil Corp. for C$2.9 billion. T...
Jonathon Brown | June 22, 2023 |

U.S. Biotech Makes 'The Acquisition We Were Waiting For'

By tucking in this retinal gene therapy firm, the Massachusetts-based company gains assets and synergy. In a March 4 BTIG research note, analyst Thomas Shrader reported that Biogen Inc. (BIIB:NASDAQ) entered into an agreement to acquire Nightstar Therapeutics Pl...
Streetwise Reports | March 7, 2019 |

Coverage Initiated on 'Solid Platform Company' with Sanofi Partnership

The reasons why this biopharma makes a compelling investment are outlined in a ROTH Capital Partners report. In a June 18 research note, analyst Tony Butler reported that ROTH Capital Partners initiated coverage on Translate Bio (TBIO:NASDAQ) , in advan...
Streetwise Reports | June 27, 2019 |

The Barriers to Investing in Private Equity Are Too High

The rich are getting richer and the poor are getting poorer, and for that we can largely blame policies of envy that increasingly restrict investors’ access to wealth-building instruments. Case in point: I was recently invited to participate in a pri...
Frank Holmes | October 15, 2019 |

Axsome Therapeutics Shares Open 82% Higher on Phase 3 MDD Trial Outcome

Axsome Therapeutics shares reached a new 52-week high price today after the company reported that its AXS-05 drug achieved primary endpoint in the GEMINI Phase 3 trial in Major Depressive Disorder. The firm indicated that the positive results support a New Drug Application fil...
Streetwise Reports | December 17, 2019 |

BARDA Award Provides 'Lift-off for Biotech's COVID Vaccine'

The ways in which Moderna is to use the funds are explained and an update on its coronavirus vaccine is provided in a ROTH Capital Partners report. In an April 19 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that the Biomedical Advanc...
Streetwise Reports | April 23, 2020 |

Oil speculators can profit from new Iranian sanctions

Growing up in Massachusetts, my mother used to say, "Live long enough, and you'll see just about anything happen in politics." And she was right. A wrestler, a standup comic, several movie actors, and former sports figures have been elected to office; t...
Kent Moors | October 28, 2012 |
1 2 3